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Abstract
Introduction: Whether early antiretroviral therapy (ART) initiation could impact sexual risk behaviours remains to be
documented.We aimed to investigate changes in sexual behaviours within the 24 months following an early versus standard ART
initiation in HIV-positive adults with high CD4 counts.
Methods: We used data from a prospective behavioural study nested in a randomized controlled trial of early ART (Temprano-
ANRS12136). Time trends in sexual behaviours from enrolment in the trial (M0) to 12-month (M12) and 24-month (M24) visits
were measured and compared, using Generalized Estimating Equations models, between participants randomly assigned either
to initiate ART immediately (early ART) or to defer ART initiation until on-going WHO starting criteria are met (standard ART).
Indicators of sexual behaviours included 1) sexual activity in the past year, 2) multiple partnership in the past year, 3)
unprotected sex at last intercourse and 4) risky sex (i.e. unprotected sex with a partner of HIV negative/unknown status) at last
intercourse.
Results: Analyses included 1952 participants (975 with early ART and 977 with standard ART; overall median baseline CD4 count:
469/mm3). Among participants with early ART, significant decreases were found between M0 and M24 in sexual activity (Odds
Ratio [OR] 0.72, 95% Confidence Interval [95% CI] 0.570.92), multiple partnership (OR 0.57, 95% CI 0.410.79), unprotected sex
(OR 0.59, 95% CI 0.470.75) and risky sex (OR 0.58, 95% CI 0.450.76). Among participants with standard ART, sexual behaviours
showed similar trends over time. These decreases mostly occurred within the 12 months following enrolment in the trial in both
groups and prior to ART initiation in participants with standard ART. For unprotected sex and risky sex, decreases were or tended
to be more pronounced among patients reporting that their last sexual partner was non-cohabiting.
Conclusions: In these sub-Saharan adults with high CD4 counts, entry into HIV care, rather than ART initiation, resulted in
decreased sexual activity and risky sexual behaviours. We did not observe any evidence of a risk compensation phenomenon
associated with early ART initiation. These results illustrate the potential behavioural preventive effect of early entry into care,
which goes hand in hand with early ART initiation.
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Introduction
With the preventive effect of early antiretroviral therapy
(ART), demonstrated by the HPTN052 trial among stable sero-
discordant couples [1], the Test and Treat prevention strategy
appears as a promising way to curb the HIV epidemic in sub-
Saharan Africa [2]. This strategy consists of universal HIV
testing, coupled with immediate ART initiation in those diag-
nosed HIV positive, regardless of their CD4 count. Estimates
of the preventive population-level impact of this strategy are
mostly derived from models relying on the hypothesis, yet to
be proven, that sexual behaviours would not change after
early ART initiation [2,3].
The possibility of risk compensation  increase in risk
behaviours as a consequence of decreased perceived risks
of HIV burden and/or transmission  may be of particular
concern [4,5]. Increase in sexual risk behaviours associated
with ART initiation has been previously reported among
high-risk groups early in the ART era [6,7], and early models
predicted that increases in risk behaviours associated with
expanded ART could offset the preventive beneficial impact
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of ART [8,9]. More recently, risk compensation has been sug-
gested to explain the limited impact of ART for reducing HIV
incidence in high-resource settings with high rates of HIV
testing and treatment coverage [10]. However, such an effect
of ART on sexual behaviours, if any, may vary depending on
the context. According to a recent review of 17 observational
studies conducted in resource-limited settings [11], only
one study conducted in Coˆte d’Ivoire reported increased
unprotected sex after ART initiation [12]. The remaining 16
studies documented decreased levels of sexual risk beha-
viours associated with ART initiation according to national or
international guidelines. These results suggested a beneficial
behavioural impact of treatment initiation. They did not
investigate, though, whether this effect was due to ART itself
or to entry into care.
To date, the consequences of ART initiation on sexual be-
haviours have mostly been studied in the context of standard
ART initiation, that is, among patients with a clinically and/or
biologically advanced HIV disease requiring treatment initia-
tion as recommended by the World Health Organisation
(WHO) [13,14]. Health status plays a central role in sexual
behaviours, especially in the context of HIV infection [1517].
Therefore, the effect of ART on sexual behaviours could be
different when ART is started earlier, that is, in healthier
patients potentially more sexually active. In addition, sexual
and preventive behaviours, such as condom use or HIV status
disclosure to partners, have been documented to differ
according to the type of partnership [1821], suggesting
that ART initiation may have different consequences on sexual
behaviours in the case of stable or occasional partnership.
We used data from the on-going Temprano ANRS-12136
randomized controlled trial to measure changes in sexual
behaviours within the 24 months following early ART initia-
tion and to compare these changes to those observed in
patients starting ART according to WHO guidelines. We also
investigated differences in sexual behaviours time trends
according to the type of sexual partnership.
Material & Methods
Temprano ANRS-12136 trial
Temprano is a multicentre, randomized open-label super-
iority trial to assess the benefits and risks of initiating ART
earlier than currently recommended by WHO, concomitantly
or not with a six-month isoniazide prophylaxis for tubercu-
losis (IPT). The trial was launched in March 2008 in Abidjan,
Coˆte d’Ivoire, and is still on-going. It will end in December
2014. The trial protocol was approved by the Coˆte d’Ivoire
national ethics committee and by the institutional review
board of the French National Agency for Research on AIDS
and viral hepatitis (ANRS, Paris, France). It has been reg-
istered on clinicaltrials.gov under the following identifier:
NCT00495651.
Between March 2008 and July 2012, patients attending
nine healthcare settings were included in the trial whenever
they met the following criteria: informed consent signed; age
18 years; HIV-1-positive; no on-going active tuberculosis;
no on-going pregnancy or breastfeeding; CD4 count B800/
mm3 and no criteria for starting ART according to the most
recent WHO guidelines. Participants were randomized into
four arms: two ‘‘standard ART’’ arms (arms 1 and 2), in which
ART was deferred until patients meet on-going WHO starting
criteria [13,14]; and two ‘‘early ART’’ arms (arms 3 and 4), in
which ART was initiated immediately at enrolment. In arms
2 and 4, participants received a six-month IPT, starting at
month-1 visit. Once included, participants were asked to
show up for trial scheduled visits at day 8, month 1, month 2,
month 3, and every three months thereafter. Standardized
questionnaires were used to record baseline and follow-up
characteristics. The trial sample included 2076 participants.
Each participant will be followed-up during 30 months. The
main outcome of the trial is the occurrence of a new episode
of severe morbidity and any event leading to death.
Socio-behavioural study
The present socio-behavioural study was nested in the
Temprano trial. Starting from 1st January 2010, standardized
questionnaires were used to collect information on partici-
pants’ sexual behaviours during the past year and on the
characteristics of their last sexual intercourse (type of partner-
ship [cohabiting or not]; HIV status of the partner [negative,
positive or unknown]; condom use). Questionnaires were
administered face-to-face by trained interviewers at enrol-
ment and at 12-month and 24-month visits except for delayed
ART initiators in the standard ART arms who completed the
questionnaire at enrolment, at ART initiation and then 12
months and 24 months after ART initiation. Patients included
before January 2010, although they did not complete a socio-
behavioural questionnaire at baseline, participated in the
socio-behavioural study during their follow-up at the same
tempo as those enrolled from 1st January 2010.
Study outcomes
Four indicators of sexual behaviours were considered: 1)
sexual activity (i.e. at least one sexual intercourse) in the
past year; 2) multiple partnership (i.e. at least two sexual
partners) in the past year; 3) unprotected sex at last inter-
course in the past year; and 4) risky sex (defined as unpro-
tected sex with a partner of HIV negative/unknown status) at
last intercourse in the past year.
Statistical analysis
All trial participants having completed a socio-behavioural
questionnaire at one or more of the following trial visits were
included in the present analysis: 1) M0 (inclusion visit), 2)
M12 (1293 months after inclusion) and 3) M24 (2496
months after inclusion). For all analyses, participants of arms
1 and 2 were grouped together in a single group referred
to as ‘‘standard ART’’ and participants of arms 3 and 4 were
grouped together in a single group referred to as ‘‘early ART.’’
Time trends in the four indicators of sexual behaviours
from M0 to M12 and M24 visits were measured and com-
pared between participants with early versus standard ART.
To account for multiple observations per individual, marginal
Generalized Estimating Equations models (GEE) of logistic
regression assuming an exchangeable correlation structure
were used. Covariates included in the models were ART
group and time period, coded as a three-level factor in order
to allow non-linear changes across time. An interaction term
between ART group and time period was added to each
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model in order to assess differences in time trends according
to ART strategy.
In order to investigate different patterns of sexual behav-
iours according to the type of partnership, we performed
interaction tests to assess whether sexual behaviours trends
over time differed between sexually active individuals with
cohabiting vs. non-cohabiting partners.
Finally, in order to assess the role on behaviours changes
of, respectively, entry into care and ART initiation, we des-
cribed changes in sexual behaviours before versus after ART
initiation among participants of the standard ART group. For
this complementary analysis, we used GEE models including
time periods coded as a four-level factor: 1) M0 (inclusion
visit), 2) TI (at Treatment Initiation, allowing for a varying
time period between M0 and TI for each individual), 3) TI12
(1293 months after TI), and 4) TI24 (2496 months after TI).
All analyses were conducted using SAS version 9.3 (SAS
Institute, Cary, North Carolina, USA).
Results
Study population
A total of 1952 participants (standard ART: 977; early ART:
975) completed at least one socio-behavioural questionnaire
in due time and were included in the present analysis,
accounting for a total of 3364 questionnaires (standard ART:
1653; early ART: 1711). As of March 1st, 2013, participants
had been followed during a mean time of 25.7 months
(Interquartile Range [IQR]: 23.930.0), and 57% of partici-
pants had completed at least two socio-behavioural ques-
tionnaires, with no difference between both ART groups
(Supplementary file).
Median age at baseline was 35 years and 79% of parti-
cipants were women. Median baseline CD4 cell count was
469/mm3 (IQR 379577). No significant difference in baseline
socio-demographic and clinical characteristics was observed
between patients of standard vs. early ART groups (Table 1).
Sexual behaviours within the 24 months following inclusion
The frequency of sexual activity decreased from 79.9% at M0
to 72.6% at M24 among participants with early ART and from
75.9 to 69.8% among participants with standard ART (Figure
1a). At the same time, the frequency of multiple partnership
decreased from 14.4 to 8.7% in the early ART group and
from 12.8 to 7.6% in the standard ART group (Figure 1b).
Frequencies of unprotected sex were 40.7% among partici-
pants with early ART and 38.1% among those with standard
ART at baseline, decreasing to 27.3 and 23.9%, respectively,
at M24 (Figure 1c). The frequency of risky sex decreased
from 26.8% at M0 to 17.3% at M24 among participants with
early ART and from 28.4% at M0 to 15.5% at M24 among
participants with standard ART (Figure 1d).
As shown in Table 2, frequencies of sexual activity, multiple
partnership, unprotected sex and risky sex significantly
decreased between M0 and M12 in both ART groups (each
Odds Ratio [OR] comparing M12 to M0 taking a value of less
than 1, with corresponding pB0.01); with the exception of
sexual activity in the standard ART group, which showed
borderline significant decrease over time (ORM12 vs. M0 0.80;
95% Confidence Interval [95%CI] 0.641.01]). Subsequently,
for the four indicators, the frequencies did not significantly
change between M12 and M24 (each p 0.05).
No significant interaction between study group and time
was found for any of the four sexual behaviours indicators
(each p0.15), suggesting that time trends between M0 and
M24 in these various indicators did not significantly differ
across ART strategies.
A complementary analysis was conducted, restricting the
GEE analysis 1) to sexually active participants and 2) to
participants reporting no condom use at last intercourse. In
both cases, the decrease in risky sex between M0 and M12
remained statistically significant (data not shown).
Differences according to the type of partnership
Among sexually active participants, the overall propor-
tion reporting that their last partner was non-cohabiting
was 39.9% at M0; 40.1% at M12; and 42.7% at M24.
Table 1. Baseline socio-demographic and clinical characteris-
tics of participants of standard and early antiretroviral therapy
(ART) groups
Standard ART Early ART p
Sex 0.31
Men 219 (22.4%) 200 (20.5%)
Women 758 (77.6%) 775 (79.5%)
Age 35 [3042] 35 [3042] 0.69
Educational level 0.61
None 236 (24.2%) 257 (26.4%)
Primary 281 (28.7%) 276 (28.3%)
Secondary 327 (33.5%) 324 (33.2%)
Secondary 133 (13.6%) 118 (12.1%)
Personal source of income 0.35
No 238 (25.4%) 256 (27.3%)
Yes 700 (74.6%) 682 (72.7%)
Family status 0.57
Single 417 (42.7%) 414 (42.5%)
Living in union 460 (47.1%) 447 (45.8%)
Separated/widowed 100 (10.2%) 114 (11.7%)
HIV-status disclosure to the partner 0.92
No 467 (52.0%) 467 (52.2%)
Yes 432 (48.0%) 428 (47.8%)
WHO clinical stage 0.88
1 632 (64.8%) 622 (63.8%)
2 252 (25.8%) 262 (26.9%)
3 86 (8.8%) 87 (8.9%)
4 6 (0.6%) 4 (0.4%)
CD4 count cell (/mm3) 470 [375573] 468 [384580] 0.48
Socio-behavioural study nested in the Temprano Trial (N1952);
patients in the standard ART group deferred ART initiation until on-
going WHO starting criteria were met, whereas patients in the early
ART group initiated ART immediately on inclusion in the trial; counts
(%) and Chi-squared p-values are presented for categorical measures.
Percentages are computed as fractions of non-missing observations.
Medians (interquartile ranges) and t-test p-values are presented for
quantitative measures.
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These proportions were higher among women than men
(overall, 44.8% vs. 28.5%, pB103).
Regardless of ART strategy and type of partnership, fre-
quencies of multiple partnership, unprotected sex and risky
sex decreased between M0 and M12 (Table 3). For unpro-
tected sex and risky sex, these decreases were or tended to
be more pronounced among participants reporting a non-
cohabiting partner at last intercourse (ORM12 vs. M0 between
0.36 and 0.42) than among those reporting a cohabiting
partner (ORM12 vs. M0 between 0.60 and 0.77). This differ-
ential decrease was not observed for multiple partnerships.
Subsequently, frequencies of multiple partnership, unpro-
tected sex and risky sex generally did not significantly change
between M12 and M24, regardless of ART group and type of
partnership. The only exception was a significant decrease
between M12 and M24 in the frequency of unprotected sex
among participant of the standard ART group reporting a
cohabiting partner at last intercourse.
Sexual behaviours before/after ART initiation among
participants on standard ART
A total of 802 participants of the standard ART group com-
pleted at least one socio-behavioural questionnaire at the
following time points: M0, treatment initiation (TI), 12
months after TI (TI12) and 24 months after TI (TI24),
representing a total of 1455 questionnaires. Among them,
492 initiated ART (median time between enrolment and
treatment initiation: 14.0 months [IQR 8.020.1]).
Among these 802 participants, the frequency of sexual
activity did not significantly change over time between M0
and TI24 (Table 4). In contrast, frequencies of multiple
partnership, unprotected sex and risky sex significantly
decreased between M0 and treatment initiation (multiple
partnership: ORTI vs. M0 0.41, 95%CI 0.260.64; unprotected
sex: ORTI vs. M0 0.65, 95%CI 0.490.85; risky sex: ORTI vs. M0
0.62, 95%CI 0.450.84). Subsequently, the frequencies of
these three indicators did not significantly change over time
within the 24 months following treatment initiation (each
p0.15).
Discussion
In this study nested in an on-going randomized controlled
trial of early ART, we found decreases in several reported
sexual behaviours within the 24 months following inclusion.
These decreases mostly occurred within the first 12 months
following enrolment in the trial in both groups and prior to
ART initiation in participants with standard ART. They did not
differ between participants initiating ART early and those
deferring ART according to WHO recommendations, suggest-
ing that such time trends might be a result of early entry into
care rather than ART initiation (whether early or not). In
addition, regardless of ART strategy, decreases in two sexual
risk behaviours indicators, namely unprotected sex and risky
sex, tended to be more pronounced for patients reporting
non-cohabiting partners as compared to those in cohabiting
partnership.
Sexual behaviours in the context of HIV care have been
previously investigated in Coˆte d’Ivoire. Three studies con-
ducted among HIV-positive patients, both treated and un-
treated, documented levels of sexual activity in the past six
Figure 1. Sexual behaviours reported at inclusion (M0), 12-month visit (M12) and 24-month visit (M24) among participants of standard and
early antiretroviral therapy (ART) groups. Socio-behavioural study nested in the Temprano Trial (N1952).
Patients in the standard ART group deferred ART initiation until on-going WHO starting criteria were met, whereas patients in the early ART
group initiated ART immediately on inclusion in the trial.
1In the past year.
2At last intercourse in the past year.
3Defined as an unprotected intercourse with a partner of negative/unknown HIV status.
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months ranging approximately from 50 to 65% [12,22,23].
The higher level of sexual activity (71%) during the past year
reported in the present study may be explained by a longer
recall period. It may additionally be related to the better
health status of our study population, made of patients
recruited at an early stage of HIV disease. Previous studies
also reported levels of unprotected sex, as measured by
inconsistent condom use, ranging from 20 to 30% [12,22,23].
This is consistent with the 25% participants reporting un-
protected sex at last intercourse in our study.
Four indicators of sexual behaviours were used in this
study. Among these, risky sex (i.e. unprotected sex with a
partner of HIV negative/unknown status) may be considered
as the best proxy of partner’s exposure to HIV infection.
In both ART groups, the odds-ratio of reporting risky sex at
last intercourse at M24, as compared to M0, was close to
0.5. This approximately represents, when accounting for
the prevalence of risky sex, a 40% decrease at the population
level [24]. This indicator integrates different components:
sexual activity, condom use and partner’s HIV status. Com-
plementary analyses suggested that this time trend reflected
not only a decrease in overall sexual activity but also an
increase in condom use and in knowledge of partner’s HIV
status over time. Decrease in sexual activity, number of
sexual partners or unprotected intercourses have previously
been reported in the context of biomedical prevention trials
[2527]. At the community level, a substantial increase in
condom use has also been recently documented in South
Africa during ART coverage scale-up [28].
At each time step considered, we found that sexual behav-
iours did not differ according to ART strategy. This finding
might challenge the results of several literature reviews,
which pointed out decreased sexual risk behaviours asso-
ciated with ART initiation [11,2931]. However, previous
studies relied on comparisons between ART-treated versus
untreated patients in a context where routine contacts with
the care system are generally infrequent for patients not yet
ART-eligible [32]. It has been previously suggested that the
behavioural effect of ART may be due to frequent contact
with the healthcare system rather than to ART itself, con-
sidering that attendance to care provides counselling and
psychosocial support [23,33]. The similar decreases in risk
behaviours we found in both ART groups, as well as the
absence of additional decrease after treatment initiation
in the standard ART group support this hypothesis. Actually,
in the Temprano trial the frequency of clinic visits is the
same for all participants, regardless of trial arm. Besides,
the protocol did not include any additional intervention to
reduce risk behaviours apart from routine clinic-based HIV
counselling. Our results thus suggest that, as compared to an
Table 2. Time trends in sexual behaviour indicators within 24 months following enrolment in the trial among participants of
standard and early antiretroviral therapy (ART) groups
Standard ART Early ART
t1 to t2 % change
b
OR
(t2 vs. t1)
c 95% CI p % changeb
OR
(t2 vs. t1)
c 95% CI p Interaction pa
Sexual activityd 0.61
M0 to M24 6.1 0.76 [0.59; 0.96] 0.022 7.3 0.72 [0.57; 0.92] 0.008
M0 to M12 4.4 0.80 [0.64; 1.01] 0.062 8.5 0.70 [0.57; 0.87] 0.002
M12 to M24 1.7 0.94 [0.79; 1.11] 0.45 1.2 1.03 [0.87; 1.22] 0.77
Multiple partnershipd 0.64
M0 to M24 5.2 0.55 [0.38; 0.80] 0.002 5.7 0.57 [0.41; 0.79] B103
M0 to M12 6.4 0.49 [0.34; 0.70] B103 5.8 0.60 [0.44; 0.83] 0.002
M12 to M24 1.2 1.13 [0.78; 1.64] 0.48 0.1 0.94 [0.69; 1.27] 0.63
Unprotected sexe 0.16
M0 to M24 14.2 0.50 [0.39; 0.64] B103 13.4 0.59 [0.47; 0.75] B103
M0 to M12 10.5 0.61 [0.48; 0.78] B103 14.7 0.55 [0.43; 0.70] B103
M12 to M24 3.7 0.83 [0.68; 1.01] 0.06 1.3 1.09 [0.89; 1.32] 0.41
Risky sexe,f 0.56
M0 to M24 12.9 0.48 [0.36; 0.63] B103 9.5 0.58 [0.45; 0.76] B103
M0 to M12 11.8 0.52 [0.39; 0.69] B103 10.4 0.55 [0.42; 0.72] B103
M12 to M24 1.1 0.93 [0.74; 1.17] 0.52 0.9 1.06 [0.84; 1.34] 0.64
Socio-behavioural study nested in the Temprano Trial (N1952); patients in the standard ART group deferred ART initiation until on-going WHO
starting criteria were met, whereas patients in the early ART group initiated ART immediately on inclusion in the trial; ap-value of the overall
likelihood-ratio test for interaction between ART group and time (for the whole M0M24 period); bchange in percentage points between t1
and t2;
codds ratio of reporting the corresponding sexual behaviour at t2 as compared to t1 (logistic regression model with Generalized
Estimating Equations); din the past year; eat last intercourse in the past year; fdefined as an unprotected intercourse with a partner of negative/
unknown HIV status; M0: at inclusion in the trial; M12: 12 months after inclusion; M24: 24 months after inclusion; OR: Odds Ratio;
CI: Confidence Interval.
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Table 3. Time trends in sexual behaviours indicators within 24 months following enrolment in the trial among participants of standard and early antiretroviral therapy (ART) groups, by
type of partnership
Standard ART Early ART
Cohabiting partner Non-cohabiting partner Cohabiting partner Non-cohabiting partner
OR
(t2 vs. t1)
b 95% CI p
OR
(t2 vs. t1)
b 95% CI p Interaction pa
OR
(t2 vs. t1)
b 95% CI p
OR
(t2 vs. t1)
b 95% CI p Interaction pa
Multiple partnershipc 0.92 0.48
M0 to M12 0.44 [0.23; 0.84] 0.013 0.52 [0.31; 0.87] 0.012 0.59 [0.36; 0.96] 0.033 0.64 [0.39; 1.05] 0.07
M12 to M24 1.22 [0.64; 2.32] 0.55 1.16 [0.69; 1.94] 0.57 0.70 [0.39; 1.23] 0.21 0.98 [0.62; 1.54] 0.93
Unprotected sexd 0.038 0.15
M0 to M12 0.77 [0.54; 1.10] 0.15 0.41 [0.26; 0.64] B.001 0.68 [0.48; 0.95] 0.023 0.41 [0.26; 0.66] B103
M12 to M24 0.68 [0.52; 0.89] B.001 1.18 [0.79; 1.77] 0.43 1.11 [0.84; 1.46] 0.48 1.10 [0.72; 1.66] 0.67
Risky sexd,e 0.27 0.048
M0 to M12 0.60 [0.42; 0.86] 0.006 0.42 [0.26; 0.68] B.001 0.77 [0.56; 1.07] 0.12 0.36 [0.22; 0.60] B103
M12 to M24 0.78 [0.59; 1.03] 0.08 1.16 [0.76; 1.78] 0.48 0.94 [0.69; 1.28] 0.68 1.33 [0.85; 2.09] 0.21
Socio-behavioural study nested in the Temprano Trial (N1642 sexually active participants); patients in the standard ART group deferred ART initiation until on-going WHO starting criteria were met,
whereas patients in the early ART group initiated ART immediately on inclusion in the trial; ap-value of the overall likelihood-ratio test for interaction between type of partnership and time (for the whole
M0M24 period); bodds ratio of reporting the corresponding sexual behavior at t2 as compared to t1 (logistic regression model with Generalized Estimating Equations);
cin the past year; dat last
intercourse in the past year; edefined as an unprotected intercourse with a partner of negative/unknown HIV status; M0: at inclusion in the trial; M12: 12 months after inclusion; M24: 24 months after
inclusion, OR: Odds Ratio: CI: Confidence Interval.
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entry into standard care at early stage of the HIV-infection,
early ART initiation per se did not differently impact sexual
behaviours.
The dynamics of the changes in sexual behaviours found
in this study is consistent with previous results. A study
conducted in Uganda indicated a dramatic decrease in unpro-
tected sex at last intercourse during the first year following
standard ART initiation, and then a stabilized level during the
two subsequent years [34]. Our findings suggest that changes
in sexual behaviours occur immediately after inclusion in the
trial. These changes might integrate modifications in sexual
behaviours resulting from the announcement of HIV diag-
nosis [35,36]  which probably occurred shortly before
enrolment in our study population with high baseline CD4
levels. Subsequently, after 12 months of follow-up, we did
not observe further decrease in sexual behaviours indicators.
Neither did we observe any ‘‘prevention fatigue’’ (i.e. a
decrease in preventive behaviours over time) as previously
reported among high-risk groups [37]. However, our results
were obtained within a relatively short follow-up time (24
months). Further studies are needed to measure long term
changes in sexual behaviours after early entry into care.
We additionally found that decreases in sexual risk behav-
iours were more pronounced among patients reporting that
their last sexual partner was non-cohabiting versus cohabit-
ing. This differential decrease may reflect a lower level of
condom use among cohabiting versus non-cohabiting  or
respectively spousal and non-spousal  relationships, as
observed in other African settings [19,20]. It may also reflect
the fact that it is more difficult to modify sexual behaviours
once they are already established in a couple. In both cases,
these results underline the need for specific prevention
messages oriented towards well-established couples.
Our results also provide insights into the issue of risk
compensation. We did not find any increase in sexual risk
behaviours as a result of early ART initiation, an intervention
conferring a strong preventive effect against HIV transmis-
sion. Actually, we found that sexual risk behaviours were
similar whether participants received the intervention or not,
and that levels of risk behaviours decreased rather than
increased following inclusion in the trial, regardless of ART
strategy. These findings, although they provide evidence
against the existence of a phenomenon of risk compensation
associated with early ART initiation, must be interpreted with
caution. Temprano is a clinical trial which primary objective is
to measure the individual rather than collective benefits and
risks of early ART. Thus, before the implementation of the
2012 WHO guidelines [38], no specific information on the
preventive effects of ART was provided to trial participants.
Whether participants have received this information from
other sources of information following the publication and
media exposure of the HPTN052 trial results [1] is unknown.
To our knowledge, this study is the first one to prospec-
tively document detailed sexual behaviours following early
ART initiation. Its major strengths are the large and ran-
domized nature of the datasets. However, we acknowledge
that our results may be subject to some biases. First, this
study relies on self-reported sexual behaviours, which may
have been under-reported as a result of social desirability.
In order to prevent such a bias, interviewers were trained
to administer questionnaires in a non-judgmental way and
interviews were conducted confidentially in private rooms. In
addition, a literature meta-analysis showed that a face-to-
face interview does not always yield to lower estimates of
sexual risk behaviours as compared to alternative interview-
ing tools [39]. Actually, we found higher levels of sexual
activity than previous studies conducted among HIV-positive
patients in Coˆte d’Ivoire [12,22,23]. This suggests that our
results are unlikely to be explained by this sole bias. Second,
given the design of the study, it is difficult to disentangle the
effect of entry into care from that of enrolment in the trial to
explain our results. Of note, Temprano is not a prevention
trial but a clinical trial in which only conventional HIV coun-
selling as provided in routine HIV care is offered. Besides,
our sample was made of patients recruited in nine clinical
centres reflecting the diversity of HIV care offered in Abidjan
(hospitals, private clinics, NGO and primary care centres). In
each participating centre, all eligible patients were system-
atically approached to participate in the trial. The total refusal
rate was quite low (16%), indicating a limited selection bias.
Taken together, these arguments suggest that the trends in
Table 4. Time trends in sexual behaviours indicators before and after standard antiretroviral therapy (ART) initiation among
participants of the standard ART group
Sexual activitya Multiple partnershipa Unprotected sexb Risky sexb,c
OR
(t2 vs. t1)
d 95% CI p
OR
(t2 vs. t1)
d 95% CI p
OR
(t2vs. t1)
d 95% CI p
OR
(t2vs. t1)
d 95% CI p
M0 to TI 0.91 [0.70; 1.19] 0.50 0.41 [0.26; 0.64] B103 0.65 [0.49; 0.85] 0.002 0.62 [0.45; 0.84] 0.002
TI to TI12 0.96 [0.76; 1.21] 0.73 0.98 [0.55; 1.72] 0.93 1.08 [0.84; 1.37] 0.56 0.91 [0.68; 1.21] 0.52
TI12 to
TI24
0.96 [0.78; 1.18] 0.68 0.65 [0.34; 1.23] 0.19 0.86 [0.70; 1.09] 0.22 0.88 [0.67; 1.15] 0.35
Socio-behavioural study nested in the Temprano Trial (N802); patients in the standard ART group deferred ART initiation until on-going WHO
starting criteria were met; ain the past year; bat last intercourse in the past year; cdefined as an unprotected intercourse with a partner of
negative/unknown HIV status; dodds Ratio of reporting the corresponding sexual behavior at t2 as compared to t1 (logistic regression model with
Generalized Estimating Equations); M0: at inclusion in the trial; TI: at treatment initiation; TI12:12 months after ART initiation; TI24:24 months
after ART initiation; OR: Odds Ratio: CI: Confidence Interval.
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sexual behaviours we describe here are also likely to be
observed after early entry into care in ‘‘real world’’ settings.
Conclusions
Through its biological effect, early ART initiation reduces
the risk of transmitting HIV from HIV-positive individuals to
their sexual partners, which has been documented among
the same study population [40]. The present study did not
document any evidence of a risk compensation phenomenon
associated with early ART initiation. Our results rather sug-
gest that early entry into care, which goes hand in hand with
early ART initiation, also carries a substantial behavioural
preventive effect. This underlines that, concurrently with
the prevention potential of ART, conventional interventions
targeting behaviours still have a role to play within combined
prevention strategies.
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